(AOF) – In the first quarter, Virbac’s turnover stood at 345.7 million euros, up 9.8% at real rates compared to the same period of 2023. The specialist in animal health specifies that after restatement of the unfavorable impact resulting from the evolution of monetary parities, the growth in turnover over the period reached 10.8%. The integration of the Globion company acquired in India last November contributed 1.1 points of growth. Excluding acquisition and at constant exchange rates, revenue growth was 9.7%.
In 2024, at constant exchange rates and scope, Virbac forecasts growth in turnover estimated, at this stage, between 4% and 6% as well as a ratio of “current operating income, before amortization of assets resulting from acquisitions “(Adjusted Ebit) on “turnover” around 15%.
Excluding acquisitions, the cash position should improve by 30 million euros, taking into account the acceleration of R&D efforts as well as the investments planned over the period, estimated at around 100 million euros.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.